© 2025 HSP News Service, L.L.C.
In a study reported in JAMA Oncology, Pickersgill et al found that individuals without prostate cancer undergoing annual prostate-specific antigen (PSA) testing often exhibited a PSA level below biopsy threshold in the year following an elevated test result. Study Details The study involved data on ...
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation...
Assessment with a genomic test could help predict which patients with recurrent prostate cancer are most likely to benefit from the addition of hormonal therapy to radiation following prostatectomy, according to findings from the phase II BALANCE trial (NRG GU006) presented in a press briefing...
A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone. The phase II LUNAR trial is the...
Atish D. Choudhury, MD, PhD, a medical oncologist and clinical/translational investigator at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discusses current guideline recommendations for the use of relugolix and leuprolide, relugolix as a combination backbone, and important considerations when applying these data to clinical practice. References 1. De La Cerda J, Dunshee C, Gervasi L, et al: A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced prostate cancer. Target Oncol 3:383-390, 2023. 2. George DJ, Saad F, Cookson MS, et al: Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer 3:383-392, 2023. 3. Brown G, Belkoff L, Hafron JM, et al: Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases. Target Oncol 1:95-103, 2023.
Atish D. Choudhury, MD, PhD, a medical oncologist and clinical/translational investigator at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discusses forms of hormonal therapy for patients with prostate cancer, with a focus on the HERO trial, which evaluated oral relugolix vs injectable leuprolide in patients with advanced hormone-sensitive disease. Dr. Choudhury touches on additional analyses from HERO as well, including the effects seen with relugolix on major cardiovascular events. References 1. Shore ND, Saad F, Cookson MS, et al: Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187-2196, 2020. 2. Saad F, George DJ, Cookson MS, et al: Relugolix vs leuprolide effects on castration resistance-free survival from the phase 3 HERO study in men with advanced prostate cancer. Cancers 15:4854, 2023. 3. Tombal B, Collins S, Morgans AK, et al: Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: Results from the phase 3 HERO study. Eur Urol 6:579-57, 2023. 4. Spratt DE, George DJ, Shore ND, et al: Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA Oncol 5:594-602, 2024.
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
Acute cystitis signaled the presence of urogenital cancers in middle-aged men and women, according to the results of a Swedish cohort study published in BMJ Public Health. Based on these findings, the researchers suggested that acute cystitis could be used as a clinical marker for urogenital...
In a Canadian phase II trial (GROUQ-PCS 9) reported in The Lancet Oncology, Niazi et al found that the addition of metastasis-directed stereotactic body radiotherapy (SBRT) to standard systemic therapy improved radiographic progression-free survival in patients with oligometastatic...
The American Cancer Society (ACS) has released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate cancer incidence rates have reversed from a decline of 6.4% per year during 2007 through 2014 to an...
Use of the PARP inhibitor niraparib in combination with the androgen biosynthesis inhibitor abiraterone acetate and the corticosteroid prednisone reduced the risk of disease progression, both radiographic and symptomatic, in patients with metastatic castration-sensitive prostate cancer harboring...
A novel, urine-based, three-biomarker panel demonstrated significant accuracy and promising sensitivity and specificity for the detection of prostate cancers during development and validation testing, according to findings published in eBioMedicine. “This new biomarker panel offers a promising,...
In a study reported in JAMA Network Open, Balmaceda et al found that rural patients in North Carolina with newly diagnosed prostate cancer were more likely to experience biochemical recurrence than were urban patients. Study Details This cohort study used data from the North Carolina Prostate...
Use of prostate-specific membrane antigen (PSMA) PET/CT before undergoing salvage radiotherapy was associated with an improved overall survival and biochemical recurrence–free survival compared those who did not receive PSMA PET/CT scanning in male patients with biochemically recurrent prostate...
As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprostatic tumor in patients receiving external-beam radiotherapy (EBRT) for localized prostate cancer....
In a substudy of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that baseline prostate-specific membrane antigen (PSMA)–positron-emission tomography (PET) total tumor volume (TTV) was prognostic for overall survival and predictive for a beneficial effect on ...
In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC). Study Details The multicenter...
Patients classified with "grade group 1" prostate cancer face a wide range of long-term outcomes, according to findings from a study published in JAMA Oncology. Investigators revealed that as many as one in six men with grade group 1 prostate cancers have intermediate- or high-risk disease when...
Based on the results of an analysis reported in JAMA Network Open by Zhang et al, preexisting depression is associated with an increased risk of mortality from prostate cancer. The investigators commented, “Approximately one in six patients with prostate cancer experience major depression, a...
As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (CRPC) cohort of the phase III TALAPRO-2 trial showed a significant benefit with the addition of talazoparib to...
As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benefit in a cohort of patients with metastatic castration-resistant prostate cancer (CRPC) unselected...
In a phase III trial (part of the STAMPEDE platform) reported in The Lancet Oncology, Gillessen et al investigated the survival outcomes of adding metformin to standard of care (SOC) in nondiabetic patients with metastatic hormone-sensitive prostate cancer starting androgen-deprivation therapy...
A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...
This is Part 3 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the management of recurrent low-volume metastatic hormone-sensitive prostate cancer (mHSPC). The patient is a 62-year-old man with a history of localized prostate cancer treated with radical prostatectomy 3 years ago. His PSA has started to increase over the past 6 months and is now 0.7 ng/mL. His comorbidities include metabolic syndrome. A PSMA PET scan reveals several retroperitoneal lymph node metastases and a small pelvic lesion. In the conversation that follows, the faculty discuss whether systemic treatment or metastasis-directed therapy would be more appropriate for this patient with recurrent low-volume mHSPC, factors (including genetic testing) that influence the optimal duration of treatment, and managing cardiovascular risk factors.
This is Part 2 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of high-risk de novo metastatic hormone-sensitive prostate cancer (mHSPC). The patient is a 62-year-old man with benign prostatic hyperplasia who has noted worsening urinary symptoms over the past 12 weeks. His PSA is 9.3 ng/mL, and a prostate biopsy demonstrates Gleason 4+4, grade group 4 prostate adenocarcinoma. Conventional CT is negative for metastatic disease, but PSMA PET/CT reveals multiple areas of vertebral body involvement and retroperitoneal lymph node metastases. He has no actionable alterations. In the conversation that follows, the faculty discuss how the imaging findings impact treatment considerations for this patient with high-volume mHSPC, whether treatment options would change in the presence of an HRR mutation, and factors to consider when choosing an androgen receptor pathway inhibitor.
As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (ARPI) in patients with castration-resistant prostate cancer with extrapelvic soft-tissue metastases...
This is Part 1 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of de novo high-volume metastatic hormone-sensitive prostate cancer with PTEN deficiency. The patient is a 68-year-old man who presented with worsening back pain. X-rays demonstrated an area in L1 concerning for metastatic cancer, and he had a prostate-specific antigen of 23 ng/mL. After a staging workup, he was found to have multifocal bone metastases consistent with de novo high-volume metastatic hormone-sensitive prostate cancer. In the conversation that follows, the faculty discuss the importance of upfront germline and somatic genetic testing in patients with mHSPC, treatment options for patients with PTEN deficiency, managing adverse events associated with capivasertib, and more.
The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting. Kidney Cancer: Long-Term...
Injection with botulinum toxin (BTX) type A (IncoA) plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA (prostate-specific membrane antigen) tumor uptake in patients with metastatic prostate cancer who were receiving...
In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...
The U.S. Food and Drug Administration (FDA) has approved a label expansion of a kit for the preparation of gallium Ga-68 gozetotide for injection (Illuccix) to include patient selection for radioligand therapy in the pre-taxane setting. The update applies to the imaging agent’s third indication,...
Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes (Abstract LBA5006).
In analyses from the phase III PSMAfore trial reported in The Lancet Oncology, Fizazi et al examined whether [177Lu]Lu–PSMA-617 (vipivotide tetraxetan; Lu-PSMA) improved patient-reported outcomes and delayed the time to first symptomatic skeletal events vs change of androgen receptor pathway (ARP)...
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...
The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...
In a long-term follow-up of the phase III MD Anderson dose-escalated, hypofractionated prostate radiation study reported in the Journal of Clinical Oncology, Hassanzadeh et al compared hypofractionated intensity-modulated radiation therapy (HIMRT) vs conventionally fractionated intensity-modulated...
Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract 5014).
Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013).
On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The oral androgen receptor inhibitor had previously been approved by the FDA in combination with docetaxel for mCSPC. Efficacy...
Researchers have identified a gene that could play a key role in the transition to a more aggressive, treatment-resistant type of prostate cancer, according to a recent study published by Duan et al in the Journal of Clinical Investigation. The findings indicated that the gene may be indirectly...
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001).
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004).
Results from the international phase III AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate plus prednisone (AAP) may help to slow cancer growth for people with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene...
Researchers may have uncovered factors contributing to poor outcomes among patients with prostate cancer, according to recent findings presented by Dall’Era et al at the 2025 ASCO Annual Meeting (Abstract 5104). The findings may lead to the development of novel targeted therapies, particularly in...
Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, which investigated enzalutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (Abstract 5005).
Treatment options for aggressive-variant prostate cancer are limited, but a subset of patients have had promising long-term responses with a combination of carboplatin plus cabazitaxel chemotherapy, followed by PARP inhibitor maintenance. This novel combination treatment approach was the focus of a ...
In a phase II trial (RAVENS) reported in the Journal of Clinical Oncology, Wang et al attempted to determine whether the addition of the bone metastasis–targeting agent radium-223 to stereotactic ablative radiotherapy improved progression-free survival as metastasis-directed therapy in patients...
Investigators may have uncovered key differences in tumor biology but similarities in survival outcomes in instances of equal access to care between non-Hispanic Black and non-Hispanic White men with metastatic prostate cancer, according to a recent study published by Valle et al in JAMA Network...
According to his office, Former President Joseph R. Biden Jr has been diagnosed with an “aggressive” type of prostate cancer that has spread to his bones. The New York Times reported that Mr. Biden’s cancer “is characterized by a Gleason score of 9 with metastasis to the bone.” The American Cancer...